UFP Technologies (UFPT) Q4 2025 earnings summary

Executive summary

• Achieved 19.5% sales growth for the year, reaching $602.8 million in revenue, nearly tripling since 2021, with record net income of $68.3 million for 2025, up 15.8% year-over-year.

• Operating income grew 14.1% to $92.3 million, and GAAP EPS increased 15.4% to $8.75; adjusted net income rose 12.7% to $76.1 million.

• Growth was led by a 23.2% rise in medical sales, partially offset by an 11.5% decline in non-medical sales.

• Integration of seven acquisitions over 2024–2025 is progressing well, supporting future growth.

• CEO transition to Mitch Rock is on track for June, with outgoing CEO remaining as executive chair for one year.

Financial highlights

• Gross margin for 2025 was 28.3%, down from 29.1% in 2024, impacted by $6.3 million in labor inefficiencies; would have been 29.3% excluding these costs.

• Adjusted operating margin for the year was 17.1%, within the 17%-20% target range; adjusted EBITDA margin was 20.1%.

• Effective tax rate dropped to 17.2% due to increased pre-tax income in the Dominican Republic.

• Generated $92 million in cash from operations; paid down $53.9 million in debt; ended year with leverage ratio of 1.1x.

• SG&A for 2025 was $77.4 million (12.8% of sales); adjusted SG&A: 11.2% of sales.

Outlook and guidance

• Continued robust growth expected in patient services, infection prevention, and robotic surgery markets, with expansion in the Dominican Republic and new program launches.

• Q1 2026 will see some lingering labor inefficiency impact, but it is expected to diminish each quarter.

• Backlog from 2025 will support 2026 revenue; backlog expected to be worked down gradually.

• No specific volume guidance for largest customer due to confidentiality, but contract extension is described as a material increase.

• Robust pipeline and new contract extensions with major customers support a bullish outlook.